Standardization of infusion solutions to reduce the risk of incompatibility

American Journal of Health-System Pharmacy

Volumn 65, Issue 17, 2008, Pages 1648-1654

  Nemec, Karin ^a   Kopelent Frank, Hannelore ^b   Greif, Robert ^a,c  

^a DANUBE HOSPITAL   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Control, quality; Critical illness; Diluents; Drug administration; Errors, medication; Hydrogen ion concentration; Incompatibilities; Injections; Stability; Standards; Storage

Indexed keywords

ADRENALIN; AMIODARONE; CLONIDINE; DOBUTAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; HALOPERIDOL; HYDROCORTISONE; HYDROCORTISONE SODIUM SUCCINATE; KETAMINE; KETANEST; MIDAZOLAM; MORPHINE; NIFEDIPINE; NIMODIPINE; NORADRENALIN; NORADRENALIN BITARTRATE; PROTON; SEDACORON; SUFENTANIL; THIOPENTAL; TIAPRIDE; UNCLASSIFIED DRUG; URAPIDIL; VENDAL;

ARTICLE; DRUG ADMINISTRATION; DRUG INCOMPATIBILITY; DRUG INFUSION; INTENSIVE CARE UNIT; MEDICATION ERROR; PRIORITY JOURNAL; STANDARDIZATION;

EID: 51649095617     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070471     Document Type: Article

References (44)

1. Ollenschlaeger G. Inkompatibilitaeten in der Infusionstherapie - eine Uebersicht. [Incompatibilities in infusion therapy - an overview.] Krankenhauspharmazie. 1984; 5:198-204. In German.
2. DeMonaco HJ. Intravenous drug compatibility. Crit Care Med. 1990; 18:896.
3. Schmitz J, Ahnefeld F. Risken der Infusionstherapie. [Risks of infusion therapy] In: Beitr Infusionsther Klin Ernaehr. 1980; 5:49-89. In German.
4. Illgen B, Koechel D. Zusatz von Infusionsloesungen zu Infusionsmischungen. [Adding infusion solutions to infusion admixtures.] Krankenhauspharmazie. 1988; 9:187-204. In German.
5. Grillo JA, Gonzalez ER, Ramaiya A et al. Chemical compatibility of inotropic and vasoactive agents delivered via a multiple line infusion system. Crit Care Med. 1995; 23:1061-6.
6. Trissel LA. Handbook on injectable drugs, 12th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2003.
7. Steffens KJ. Infusionstherapie [Infusion therapy] Melsungen: Bibliomed Verlag; 1993. In German.
8. Taxis K, Barber N. Ethnographic study of incidence and severity of intravenous drug errors. BMJ. 2003; 326:684-7.
9. Taxis K, Barber N. Causes of intravenous medication errors: an ethnographic study. Qual Saf Health Care. 2003; 12:343-8.
10. Taxis K, Barber N. Incidence and severity of intravenous drug errors in a German hospital. Eur J Clin Pharmacol. 2004; 59:815-7.
11. Cousins DH, Sabatier B, Begue E et al. Medication errors in intravenous drug preparation and administration: a multicentre audit in the UK, Germany and France. Qual Saf Health Care. 2005; 14:190-5.
12. Hoppe-Tichy T, Noe-Schwenn S, Wahlig A et al. Medikationsfehler bei der Applikation Parenteraler Arzneimittel. [Medication errors in parenteral drug administration.] Krankenhauspharmazie. 2002; 23:11-7. In German.
13. Tissot E, Cornette C, Demoly P et al. Medication errors at the administration stage in an intensive care unit. Intensive Care Med. 1999; 25:353-9.
14. Polderman KH, Girbes AJ. Central venous catheter use. Part 1: mechanical complications. Intensive Care Med. 2002; 28:1-17.
15. Polderman KH, Girbes AJ. Central venous catheter use. Part 2: infectious complications. Intensive Care Med. 2002; 28:18-28.
16. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med. 2003; 348:1123-33.
17. Schneider MP, Cotting J, Pannatier A. Evaluation of nurses' errors associated in the preparation and administration of medication in a pediatric intensive care unit. Pharm World Sci. 1998; 20:178-82.
18. Tissot E, Cornett C, Limat S et al. Observational study of potential risk factors of medication administration errors. Pharm World Sci. 2003; 25:264-8.
19. Apkon M, Leonard J, Probst L et al. Design of a safer approach to intravenous drug infusions: failure mode effects analysis. Qual Saf Health Care. 2004; 13:265-71.
20. Wheeler SJ, Wheeler DW. Medication errors in anaesthesia and critical care. Anaesthesia. 2005; 60:257-73.
21. Hadzija BW, Lubarsky DA. Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. Am J Health-Syst Pharm. 1995; 52:997-9.
22. Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products: two new methods of evaluating iv emulsion compatibility. Ann Pharmacother. 1996; 30:228-32.
23. Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm. 1997; 54:1287-92.
24. Masaki Y, Tanaka M, Nishikawa T. Physicochemical compatibility of propofollidocaine mixture. Anesth Analg. 2003; 97:1646-51.
25. Chemin EL, Smiler B. Any propofol compatibility study must include an emulsion stability analysis. Anesth Analg. 2000; 91:1307-8.
26. Driscoll DF, Bhargava HN, Li L et al. Physicochemical stability of total nutrient admixtures. Am J Health-Syst Pharm. 1995; 52:623-34.
27. Baker MT, Naguib M. Propofol: the challenges of formulation. Anesthesiology. 2005; 103:860-76.
28. Mann HJ, Demmon SL, Boelk DA et al. Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration. Am J Health-Syst Pharm. 2004; 61:2664-71.
29. Feddema S, Rusho WJ, Tyler LS et al. Physical compatibility of vasopressin with medications commonly used in cardiac arrest. Am J Health-Syst Pharm. 2003; 60:1271-2.
30. Catania PN, ed. King Guide to parenteral admixtures. www.kingguide.com (accessed 2004 Apr).
31. Forman JH, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm. 1987; 44:2298-9.
32. Le Belle MJ, Savard C, Gagnon A. Compatibility of morphine and midazolam or haloperidol in parenteral admixtures. Can J Hosp Pharm. 1995; 48:155-60.
33. Chandler SW, Trissel LA, Weinstein SM. Combined administration of opioids with selected drugs to manage pain and other cancer symptoms: initial safety screening for compatibility. J Pain Symptom Manage. 1996; 12:168-71.
34. Johnson CE, Bhatt-Mehta V, Mancari SC et al. Stability of midazolam hydrochloride and morphine sulfate during simulated intravenous coadministration. Am J Hosp Pharm. 1994; 51:2812-5.
35. Yamashita SK, Walker SE, Choudhury T et al. Compatibility of selected critical care drugs during simulated Y-site administration. Am J Health-Syst Pharm. 1996; 53:1048-51. [Erratum, Am J Health-Syst Pharm. 1997; 54:1110.]
36. Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm. 1997; 54:64-5.
37. Roy JJ, Hildgen P. Stability of morphine-ketamine mixtures in 0.9% sodium chloride injection packaged in syringes, plastic bags and medication cassette reservoirs. Int J Pharm Comp. 2000; 4:225-8.
38. Trissel LA, Martinez JF. Sufentanil data on file. Pharmaceutical Analysis Laboratory, University of Texas, M. D. Anderson Cancer Center. Houston, TX; 1995 Feb.
39. Swart EL, Mooren RA, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm. 1995; 52:2020-2.
40. Hasegawa GR, Eder JF. Visual compatibility of amiodarone hydrochloride injection with other injectable drugs. Am J Hosp Pharm. 1984; 41:1379-80.
41. Parker EA. Compatibility digest. Aramine bitartrate injection. Am J Hosp Pharm. 1969; 26:653-4.
42. Allen LV Jr, Stiles ML. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Part 2. Am J Hosp Pharm. 1981; 38:380-1.
43. Kohut J 3rd, Trissel LA, Leissing NC. Don't ignore details of drug-compatibility reports. Am J Health-Syst Pharm. 1996; 53:2339.
44. Allen LV Jr, Levinson RS, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Am J Hosp Pharm. 1977; 34:939-43.